文献速递妇科

左炔诺孕酮释放宫内装置治疗低危子宫内膜癌与复杂非典型增生

Treatment of Low-Risk Endometrial Cancer and Complex Atypical Hyperplasia With the Levonorgestrel-Releasing Intrauterine Device.
PubMed 文献 · Obstet Gynecol · 2018-01-01

本回顾性病例系列纳入2003年1月至2013年6月期间接受左炔诺孕酮释放宫内装置(LNG-IUD)治疗的复杂非典型增生或早期子宫内膜癌患者,评估其疗效及反应与临床病理因素的关系。6个月时总体缓解率为75%(95%CI 57-89),复杂非典型增生为80%(95%CI 52-96),1级子宫内膜癌为67%(95%CI 30-93),2级子宫内膜癌为75%(95%CI 35-97)。结论认为LNG-IUD保守治疗可使多数患者恢复正常组织学。

要点

  • 6个月时总体缓解率为75%(95%CI 57-89),32例可评估患者中15例为复杂非典型增生(47%)、9例为1级子宫内膜癌(28%)、8例为2级子宫内膜癌(25%)。
  • 复杂非典型增生6个月缓解率为80%(95%CI 52-96),1级子宫内膜癌为67%(95%CI 30-93),2级子宫内膜癌为75%(95%CI 35-97)。
  • 病理标本缺乏外源性孕激素效应与IUD无反应存在关联趋势(P=.05),无反应者子宫中位直径大1.3 cm(P=.04)。

核心结论

  • 左炔诺孕酮释放宫内装置保守治疗复杂非典型增生或早期子宫内膜癌可使多数患者恢复正常组织学。

研究设计与样本

  • 回顾性病例系列,纳入2003年1月至2013年6月期间因复杂非典型增生或早期子宫内膜癌接受LNG-IUD治疗的所有患者,共46例。
  • 计算缓解率并分析缓解与年龄、体重指数、子宫大小等临床病理因素的关联。

主要发现

  • 46例患者接受LNG-IUD治疗,6个月时间点32例可评估,其中复杂非典型增生15例(47%)、G1子宫内膜癌9例(28%)、2级子宫内膜癌8例(25%)。
  • 6个月时总体缓解率为75%(95%CI 57-89);复杂非典型增生为80%(95%CI 52-96),1级子宫内膜癌为67%(95%CI 30-93),2级子宫内膜癌为75%(95%CI 35-97)。
  • 病理标本缺乏外源性孕激素效应与IUD无反应存在关联趋势(P=.05)。
  • 无反应者子宫中位直径较有反应者大1.3 cm(P=.04)。

关键数值与推荐

  • 6个月总体缓解率75%(95%CI 57-89)。
  • 复杂非典型增生6个月缓解率80%(95%CI 52-96)。
  • 1级子宫内膜癌6个月缓解率67%(95%CI 30-93)。
  • 2级子宫内膜癌6个月缓解率75%(95%CI 35-97)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To assess efficacy of the levonorgestrel-releasing intrauterine device (LNG-IUD) for treatment of complex atypical hyperplasia or low-grade endometrial cancer. METHODS: This retrospective case series included all patients treated with the LNG-IUD for complex atypical hyperplasia or early-grade endometrial cancer from January 2003 to June 2013. Response rates were calculated and the association of response with clinicopathologic factors, including age, body mass index, and uterine size, was determined. RESULTS: Forty-six patients diagnosed with complex atypical hyperplasia or early-grade endometrial cancer were treated with the LNG-IUD. Of 32 evaluable patients at the 6-month time point, 15 had complex atypical hyperplasia (47%), nine had G1 endometrial cancer (28%), and eight had grade 2 endometrial cancer (25%). Overall response rate was 75% (95% CI 57-89) at 6 months; 80% (95% CI 52-96) in complex atypical hyperplasia, 67% (95% CI 30-93) in grade 1 endometrial cancer, and 75% (CI 35-97) in grade 2 endometrial cancer. Of the clinicopathologic features evaluated, there was a trend toward the association of lack of exogenous progesterone effect in the pathology specimen with nonresponse to the IUD (P=.05). Median uterine diameter was 1.3 cm larger in women who did not respond to the IUD (P=.04). CONCLUSION: Levonorgestrel-releasing IUD therapy for the conservative treatment of complex atypical hyperplasia or early-grade endometrial cancer resulted in return to normal histology in a majority of patients.

来源:Obstet Gynecol,查看原文。版权归原作者所有。

引用

  1. Pal N, Broaddus RR, Urbauer DL, et al. Treatment of Low-Risk Endometrial Cancer and Complex Atypical Hyperplasia With the Levonorgestrel-Releasing Intrauterine Device. Obstet Gynecol. 2018. PMID: 29215513. doi:10.1097/AOG.0000000000002390

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。